KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Discontinued Operations (2022 - 2025)

TherapeuticsMD (TXMD) has disclosed Cash from Discontinued Operations for 5 consecutive years, with 47000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Discontinued Operations rose 141.23% year-over-year to 47000.0, compared with a TTM value of 28000.0 through Sep 2025, up 99.16%, and an annual FY2024 reading of 438000.0, up 98.25% over the prior year.
  • Cash from Discontinued Operations was 47000.0 for Q3 2025 at TherapeuticsMD, up from 57000.0 in the prior quarter.
  • Across five years, Cash from Discontinued Operations topped out at 136716000.0 in Q2 2022 and bottomed at 131064000.0 in Q4 2022.
  • Average Cash from Discontinued Operations over 4 years is 2597200.0, with a median of 114000.0 recorded in 2024.
  • Peak annual rise in Cash from Discontinued Operations hit 141.23% in 2025, while the deepest fall reached 105.42% in 2025.
  • Year by year, Cash from Discontinued Operations stood at 131064000.0 in 2022, then skyrocketed by 97.8% to 2881000.0 in 2023, then surged by 99.83% to 5000.0 in 2024, then skyrocketed by 1040.0% to 47000.0 in 2025.
  • Business Quant data shows Cash from Discontinued Operations for TXMD at 47000.0 in Q3 2025, 57000.0 in Q2 2025, and 13000.0 in Q1 2025.